Scientific Programme
Day 1
Thursday, May 3, 2018
15:15-15:30
Welcome address by meeting Co-Chairs
Chairs: Evangelos Terpos, Greece, Hervé Avet- Loiseau, France
15:30 - 15:50
Cytogenetics and genomics: an update
Hervé Avet- Loiseau, France
Bases for immunotherapy
Paola Neri, Canada
15:50 - 16:10
Clonality
Nikhil Munshi, USA
16:10 -16:30
16:30 - 16:50
Drug combinations: role of signalling pathways
Marc Raab, Germany
Session 1: Advances in disease biology
15:30 - 16:50
16:50 - 17:10
Coffee Break& Poster Viewing
17:10 - 18:30
Session 2: Organ damage and practical considerations
Chairs: Nikhil Munshi, USA, Heinz Ludwig, Austria
17:10 - 17:30
Bone disease
Evangelos Terpos, Greece
Monoclonal gammopathy of clinical significance
Jean-Paul Fermand, France
17:30 - 17:50
Supportive care
Heinz Ludwig, Austria
17:50 - 18:10
18:10 - 18:30
Quality of life considerations in myeloma
Rachid Baz, USA
Chairs: Arnon Nagler, Israel, Steven Treon, USA
18:30 - 18:50
Latest advances in amyloidosis
Giampaolo Merlini, Italy
Advances in Waldenstrom macroglobulinemia
Steven Treon, USA
18:50-19:10
Session 3: Special lectures
18:30 - 19:10
19:15 - 20:15
Welcome Reception
Day 2
Friday, May 4, 2018
Chairs: Joan Blade, Spain, Ali Bazarbachi, Lebanon
09:30 - 10:00
Discussion
08:30 - 08:50
The optimal induction regimen
Michele Cavo, Italy
08:50 - 09:10
Role of consolidation including double autologous transplant
Pieter Sonneveld, The Netherlands
09:10 - 09:30
Maintenance therapy after autologous transplantation
Sonja Zweegman, The Netherlands
Session 4: Treatment guidelines for the young patients
08:30 - 10:00
10:00-10:30
Coffee Break, Poster Viewing & Visit the Exhibition
Chairs: Philippe Moreau, France, S. Vincent Rajkumar, USA
MRD techniques: differences between NGS and NGF
Jill Corre, France
11:30-11:50
How to define smoldering myeloma?
S. Vincent Rajkumar, USA
11:50-12:00
Discussion
10:30-10:50
Criteria for disease assessment
Joan Blade, Spain
10:50-11:10
Novel imaging techniques
Elena Zamagni, Italy
11:10-11:30
Session 5: Modern tools for disease evaluation
10:30-12:00
12:00-12:30
Lunch Break, Poster Viewing & Visit the Exhibition
12:30-13:30
13:30-13:45
Technical break
Chair: Lalit Kumar, India , Mohamad Mohty, France
14:00-14:15
The case for 2nd generation proteasome inhibitors:
Sagar Lonial, USA
13:45-14:00
The case for monoclonal antibodies:
Saad Usmani, USA
Session 6: Debate - Choice of therapy for first relapse after autologous transplant
13:45-14:15
14:15-14:35
Treatment decisions in elderly patients: different and difficult scenarios
Mohamad Mohty, France
Assessment of frailty
Alessandra Larocca, Italy
14:35-14:55
Practical considerations for the management of frail patients
Cyrille Hulin, France
14:55-15:15
15:15-15:45
Debate - Alkylating agents as part of frontline therapy in the elderly
Session 7: Treatment guidelines for elderly patients
14:15-15:45
15:45-16:15
Coffee Break, Poster Viewing & Visit the Exhibition
Chair: Laurent Garderet, France, Kwee Yong, UK
16:15-16:55
16:15-16:35
16:35-16:55
Debate - Allogeneic stem cell transplantation for high risk cytogenetics frontline
Pro: Hermann Einsele, Germany
Con: Fredrik Schjesvold, Norway
17:15 - 17:35
Practical considerations when using anti-CD38 antibodies
Torben Plesner, Denmark
17:35 - 17:55
Plasma cell leukemia
Francesca Gay, Italy
17:55 - 18:15
Niels van de Donk, The Netherlands
Latest results of immunotherapy
Sagar Lonial, USA
16:55-17:15
Session 8: Management of special situations
16:15-18:15
Chairs: Thierry Facon, France, Mohamad Mohty, France, Arnon Nagler, Israel
18:15 - 18:40
Prevention of Progression in Multiple Myeloma
Irene Ghobrial, USA
Multiple Myeloma: 25 Years of Progress
Philippe Moreau, France
18:40 - 19:05
Session 9: Special lectures
18:15 - 19:05
Day 3
Saturday, May 5, 2018